Form 4: ATAI Life Sciences Director and 10% Owner Christian Angermayer Granted 103,000 Stock Options

Christian Angermayer, a Director and 10% Owner of ATAI Life Sciences N.V., was granted 103,000 stock options with an exercise price of $2.25 per share.

Summary

• Christian Angermayer, who serves as both a Director and a 10% Owner of ATAI Life Sciences N.V. (ATAI), acquired 103,000 stock options.
• The transaction date for this acquisition was June 26, 2025.
• Each stock option has an exercise price of $2.25.
• The options are for Common Shares, with each option representing the right to acquire one common share.
• The stock options are set to expire on June 26, 2035.
• The options will vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director and significant owner is generally viewed positively as it indicates confidence in the company's future prospects and aligns insider interests with shareholder value creation.

Positives

• The acquisition of stock options by a Director and significant owner like Christian Angermayer can signal confidence in the company's future performance and long-term value.
• The options have a 10-year expiration period, allowing for a long-term perspective on potential share price appreciation.

Future Outlook

The stock options granted to Christian Angermayer are set to vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026, indicating a future milestone for the options to become exercisable.

Industry Context

The granting of stock options to directors and significant owners is a common practice in the biotechnology and pharmaceutical industries, aligning management and shareholder interests by incentivizing long-term company performance and growth.

Related Party Transactions

• The grant of 103,000 stock options to Christian Angermayer, a Director and 10% Owner, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this transaction as a positive signal of insider confidence in the company's future performance.
• The options align the interests of a key director and owner with long-term shareholder value creation.

Next Steps

• The stock options will vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026, at which point they will become exercisable.

Key Dates

Keywords

ATAI Life Sciences, Christian Angermayer, Stock Options, Insider Transaction, Form 4, Director, 10% Owner, Equity Compensation, Biotechnology, Pharmaceuticals